Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Treatment of radiation induced side-effects in prostate cancer patients with hyperbaric oxygen therapy

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

HAYATO Takeda

Citation

Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524

Authors

H. Takeda

Author affiliations

  • Urology, Nippon Medical School Main Hospital, 113-8602 - Tokyo/JP
More

Resources

Abstract 1208

Aim/Background

To evaluate the efficacy of Hyperbaric Oxygen (HBO) Therapy for prostate cancer patients who developed radiation induced side-effects.

Methods

Between April 2006 and March 2015, 14 prostate cancer patients treated with External beam radiation therapy (dosage 69.3 - 72 Gy) developed RTOG/EORTC grade 3 radiation induced side-effects at Nippon Medical School. Patients received 100% oxygen in a hyperbaric chamber at a pressure of 2.5 atmospheres absolute, 20 minutes pressurization, 60 minutes treatment, 20 minutes decompression once a day, 6 times a week. 20 HBO treatments were performed per course. After every course of HBO treatment, therapeutic effect was evaluated using RTOG/EORTC Late Radiation Morbidity Scoring Schema.

Results

The average age was 74.3 years old. 8 hemorrhagic proctitis, and 6 hemorrhagic cystitis were treated with a mean of 20 (range 10-97) HBO treatments. The mean duration for the side effect to occur was 13 months (range 6-24 months), the mean duration between the onset of side effect and beginning of HBO therapy was 10 months (range 5-18months). 6 patients completely recovered, 5 patients had improvement of side-effects, 1 patient had no improvement and was treated with argon plasma coagulation, and 1 patient could not continue the therapy.

Conclusions

HBO therapy can be a primary option for the management of radiation induced side-effects.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings